(May 12, 2021, 11:46 AM EDT) -- NEW YORK — A medical device maker and two of its senior executives violated federal securities laws by misrepresenting to investors that the although company’s net sales had grown during the second quarter of 2020, certain undisclosed factors, including the use of growth rebates and other allowances, would prevent the growth to continue in subsequent quarters, an investor alleges in a securities class action complaint filed on May 7 in New York federal court....